<DOC>
	<DOCNO>NCT00908726</DOCNO>
	<brief_summary>AquafolTM ( Daewon Pharmaceutical Co. , Ltd. , Seoul , Korea ) microemulsion propofol develop eliminate lipid solvent-related adverse event long chain triglyceride emulsion ( LCT ) propofol ( Diprivan® ; AstraZeneca , London , United Kingdom ) , infection , fat embolism , hypertriglyceridemia pancreatitis . Originally , AquafolTM formulate 8 % polyethylene glycol 660 hydroxystearate ( Solutol HS 15 , BASF Company Ltd. , Seoul , Korea ) 5 % tetrahydrofurfuryl alcohol polyethylene glycol ether ( Glycofurol , Roche , Basle , Switzerland ) . A phase 1 study ass safety tolerability polymeric vehicle formulation healthy volunteer show dose-limiting toxicity . Subsequently , reformulate 10 % purify poloxamer 188 ( PP188 ) nonionic block copolymer surfactant 0.7 % polyethylene glycol 660 hydroxystearate nonionic surfactant . Alterations propofol formulation may result altered pharmacokinetic , pharmacodynamic characteristic . The aim study compare pharmacokinetics pharmacodynamics propofol microemulsion lipid emulsion , use noncompartmental analysis population analysis mixed effect model .</brief_summary>
	<brief_title>Population Pharmacokinetics/Pharmacodynamics ( PK/PD ) Microemulsion Propofol Healthy Volunteers</brief_title>
	<detailed_description>The Subjects fast 6 h study drug administration . An 18-gauge angiocatheter place vein antecubital area . A second angiocatheter place contralateral radial artery frequent blood sampling . Subjects monitor electrocardiography , pulse oximetry , end-tidal carbon dioxide concentration , invasive blood pressure measurement ( Datex-Ohmeda S/5 ; Planar Systems , Inc. , Beaverton , OR ) Bispectral Index ( BIS ) ( Aspect 2000 ; Aspect Medical Systems , Inc. , Newton , MA ) . In addition , electroencephalographic activity seven monopolar channel ( Fp1 , Fp2 , F3 , F4 , Cz , P3 , P4 , reference A2 ) record QEEG-8 ( LXE3208 , Laxtha Inc. , Daejeon , Korea ) . The subject stratify three age group ( 19-40 , 41-64 , &gt; 65 yr ) , group include 10 male 10 female volunteer . Each subject receive propofol formulation crossover fashion separate 7-day washout period , order drug administration randomize . Subjects receive propofol formulation 60 min . The infusion rate assign accord nonblinded , randomize design 1.5 , 3 , 6 , 12 mg/kg/hr . Samples collect ethylenediaminetetraacetic acid ( EDTA ) tube centrifuge 10 min 3,500rpm . Plasma store -70°C assay . Arterial blood sample ( 4 ml ) take preset interval : 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 10 , 15 , 20 , 30 , 40 , 50 , 58 , 60 , 62 , 66 , 70 , 80 , 90 , 120 150 min administration propofol . Venous blood sample ( 4ml ) take preset interval : 180 , 240 , 300 , 600 , 720 1,200 min administration propofol . In addition , arterial sample draw LOC ( loss consciousness ) ROC ( recovery consciousness ) observe .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<criteria>ASA 1 2 ( healthy mild systemic illness ) healthy volunteer age ≥ 19 yr ASA 3 age group contraindication use propofol abnormal laboratory find clinical significance evidence pregnancy history alcohol drug abuse neurological psychiatric disease unable unwilling give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>